(NASDAQ: IBRX) Immunitybio's forecast annual revenue growth rate of 115.76% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.01%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.59%.
Immunitybio's revenue in 2026 is $113,288,000.On average, 7 Wall Street analysts forecast IBRX's revenue for 2026 to be $219,635,450,345, with the lowest IBRX revenue forecast at $181,358,860,838, and the highest IBRX revenue forecast at $276,469,451,633. On average, 6 Wall Street analysts forecast IBRX's revenue for 2027 to be $542,452,166,415, with the lowest IBRX revenue forecast at $278,792,983,524, and the highest IBRX revenue forecast at $843,740,228,596.
In 2028, IBRX is forecast to generate $1,245,042,973,216 in revenue, with the lowest revenue forecast at $774,404,392,003 and the highest revenue forecast at $1,554,504,521,472.